Satoshi Tanaka

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom.

Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom.

Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies.

Mizuho Securities Co., Ltd. (Broker) (Mizuho Securities-Broker) is the brokerage division of Mizuho Securities Co. Ltd., ultimately owned by Mizuho Financial Group, Inc. (TYO: 8411; NYSE: MFG) in Japan. The firm was originally founded in 1917 and is headquartered in Tokyo with a network of offices throughout Japan as well as overseas representation through Mizuho entities or strategic partners (in Great Britain, Switzerland, the US, Hong Kong, Mainland China, South Korea, Singapore and India). Mizuho Securities-Broker provides enhanced equity and fixed income execution services for their clients who includes private individuals in Japan, domestic and foreign institutions, non-financial companies, financial institutions and public corporations in the securities and investment banking fields.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Mina (Holdings) Ltd. is an investment holding British company founded in 2014. The private company is based in London, UK. The company's main function is to hold investments.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Jitsubo Co., Ltd. researches, develops, and produces peptides. It operates as a peptide development company that provides solutions to patients using their proprietary technologies for manufacturing and engineering peptides. The firm specializes in peptide synthesis, which enables users to modify amino acid sequence for the creation of physical, chemical, and pharmacological properties. It also engages in development of peptide pharmaceuticals, licensing regarding active ingredient manufacturing technology for peptides, and peptide drug discovery research. The company was founded by Yusuke Kohno and Kazuhiro Chiba in 2000 and is headquartered in Tokyo, Japan.

TMI Associates is a general law office based in Tokyo, Japan. The Japanese company specializes in areas of dispute and corporate fields. It is composed of lawyers, patent attorneys, and staff with experience in both domestic and public relations work. TMI Associates has established a system that can respond to a wide range of needs through partnerships with various specialized organizations. The private company was founded by Tomohiro Toyama.

Founded in 2004, Nomura Institute of Capital Markets Research is a Japanese market research company that provides market research services. Part of Nomura Holdings, Inc., the company is based in Tokyo, Japan.

Nomura Securities Co., Ltd. (NSC) is a wholly-owned brokerage subsidiary of Nomura Holdings, Inc. (TSE: 8604; NYSE: NMR). Headquartered in Tokyo, the firm was founded in 1925. NSC places a strong emphasis on research, both fundamental and quantitative. In addition to stock and bond underwriting, their activities include IPO and M&A advisory, wealth management, separately managed accounts, fund wrap services, prime brokerage and structured equity finance. Their clients include institutions, hedge funds, private banks and private equity funds as well as corporate clients and retail investors.

Nomura Asset Management Co., Ltd. (NAM) is the wholly-owned investment management subsidiary of Nomura Holdings, Inc. (TYO: 8604; NYSE: NMR) in Japan. Founded in 1959 as Nomura Securities Investment Trust Co., Ltd., the firm became Nomura Asset Management Co., Ltd. in 1997 when they merged with Nomura Investment Management Co., Ltd. Headquartered in Tokyo, NAM provides investment advisory services globally to a broad range of institutional investors as well as pooled investment vehicles, including private funds and Japanese investment trusts.

The Nomura Trust & Banking Co., Ltd. operates as a trust bank. It operates through the following business divisions: Trust Business, Banking Business, and Securities Business. The firm’s Trust Business division specializes in specified money trusts and specified pecuniary trusts; individually operated designated money and pecuniary trusts; jointly operated designated money trusts; composite trusts; pension trusts; investment trusts; securities trusts; and outsource services for investment trusts. Its Banking Business division engages in deposit taking, lending, domestic exchange business, and foreign exchange business. The firm’s Security Business division handles the investment trust, over-the-counter sales, and account administration business; corporate bond administration business; fiscal agent for corporate bonds; investment advisory and agency business; and investment management business. The company was founded on August 24, 1993 and is headquartered in Tokyo, Japan.

Japan Securities Clearing Corp. provides clearing and settlement services for securities exchanges. It offers equities and bonds, futures and options, Japanese government bonds, credit default swap and interest rate swap products. The company was founded in July 2002 and is headquartered in Tokyo, Japan.

Cable & Wireless Ltd. operates as a telecommunications company. The company was founded in 1929 and is headquartered in London, the United Kingdom.

The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.